Jayant Kumar, MD
Nephrology · Albuquerque, NMNPI 1558451039
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,176 of the $12,258 with a category attached, or 66.7%. 36 manufacturers reported payments, led by Fresenius USA Marketing, Inc. at 30.7% of the total. Reporting peaked in 2023 at $4,695 and has fallen 74.8% since, to $1,181 in 2025. Among nephrology clinicians in NM with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 286 payments — averaging $42.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Fresenius USA Marketing, Inc.$4K
- Calliditas Therapeutics US Inc.$1K
- Amgen$1K
- AstraZeneca$933
- Nxstage Medical, Inc.$823
- Vifor Pharma, Inc.$670
- plus $3K from 30 others
Across 1,042 payments — averaging $2727.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$965K
- AstraZeneca$916K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$265K
- Astrazeneca UK Limited$233K
- Vertex$137K
- Novo Nordisk AS$111K
- plus $214K from 7 others
What the payments were for
- Consulting fees$2,40020%
- Travel & lodging$1,61813%
- Food & beverage$8,17667%
- Education$641%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Fresenius USA Marketing, Inc. | 10 | $3,762 |
| Calliditas Therapeutics US Inc. | 7 | $1,371 |
| Amgen(2 entities) | 43 | $1,215 |
| AstraZeneca(2 entities) | 43 | $933 |
| Nxstage Medical, Inc. | 10 | $823 |
| Vifor Pharma, Inc. | 37 | $670 |
| Bayer | 21 | $636 |
| Daiichi Sankyo Inc. | 30 | $491 |
| Otsuka America Pharmaceutical, Inc. | 16 | $357 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $317 |
| Akebia Therapeutics Inc | 5 | $187 |
| Travere Therapeutics, Inc. | 4 | $168 |
| Boehringer Ingelheim | 4 | $152 |
| GSK | 10 | $151 |
| Sanofi | 5 | $119 |
| Medtronic | 2 | $117 |
| Outset Medical Inc | 1 | $101 |
| Novartis | 5 | $91 |
| Merck | 4 | $74 |
| Aurinia Pharma U.S., Inc. | 4 | $74 |
| Novo Nordisk | 3 | $73 |
| Veloxis Pharmaceuticals, Inc. | 1 | $67 |
| Johnson & Johnson | 3 | $51 |
| Mallinckrodt Hospital Products Inc. | 2 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| Apellis Pharmaceuticals, Inc. | 1 | $27 |
| Ascendis Pharma Endocrinology Inc | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $21 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Amicus Therapeutics, Inc. | 1 | $17 |
| Renalytix AI, Inc. | 1 | $16 |
| Covidien LP | 1 | $15 |
| Chiesi USA, Inc. | 1 | $13 |
| Mallinckrodt Enterprises LLC | 1 | $12 |
| Boston Scientific | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korsuva$3,619
- TARPEYO$1,208
- NXSTAGE SYSTEM ONE$433
- Kerendia$350
- Tavneos$349
- LIBERTY SELECT CYCLER$324
- LifeVest$124
- LOKELMA$123
- JARDIANCE$121
- Vafseo$118
- PUREFLOW SL$109
- INJECTAFER$104
- Veltassa$101
How this compares
$12,258 in reported general payments places this provider in the 90th percentile of 68 nephrology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 49 | $133,393 |
| FarxigaDapagliflozin Propanediol | 41 | $31,795 |
| Lanthanum Carbonate | 11 | $12,000 |
| LokelmaSodium Zirconium Cyclosilicate | 16 | $10,578 |
| JardianceEmpagliflozin | 13 | $9,970 |
| Sevelamer Carbonate | 57 | $8,242 |
| JanuviaSitagliptin Phosphate | 13 | $7,604 |
| Valganciclovir Hcl | 77 | $6,594 |
| VeltassaPatiromer Calcium Sorbitex | 12 | $5,964 |
| Tacrolimus | 45 | $5,043 |
| Mycophenolic AcidMycophenolate Sodium | 34 | $3,841 |
| Amlodipine Besylate | 166 | $1,845 |
| Famotidine | 180 | $1,844 |
| Calcium Acetate | 13 | $1,780 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $1,512 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $3,762 | $133,39349 claims |
| AstraZenecaFarxiga, Lokelma | $933 | $42,37457 claims |
| Boehringer IngelheimJardiance | $152 | $9,97013 claims |
| MerckJanuvia | $74 | $7,60413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 68 nephrology providers in New Mexico.
Other nephrology in Albuquerque
- Satyaki BanerjeeAlbuquerque$260K
- Christos ArgyropoulosAlbuquerque$32K
- Arun RajasekaranAlbuquerque$32K
- George Vasquez RiosAlbuquerque$25K
- Luis Madera MarinAlbuquerque$7K
- Hector CastroAlbuquerque$7K
- Chudi AdiAlbuquerque$7K
- Dale EricksonAlbuquerque$6K
- Lei ChenAlbuquerque$5K
- Sonam KundelingAlbuquerque$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.